Compare · CGC vs MDWD
CGC vs MDWD
Side-by-side comparison of Canopy Growth Corporation (CGC) and MediWound Ltd. (MDWD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and MDWD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 15.7x MDWD ($182.2M).
- Over the past year, CGC is down 35.6% and MDWD is down 35.1% - MDWD leads by 0.5 points.
- MDWD has been more active in the news (5 items in the past 4 weeks vs 3 for CGC).
- CGC has more recent analyst coverage (19 ratings vs 8 for MDWD).
- Company
- Canopy Growth Corporation
- MediWound Ltd.
- Price
- $1.04-0.95%
- $14.19-1.05%
- Market cap
- $2.86B
- $182.2M
- 1M return
- -9.57%
- -18.00%
- 1Y return
- -35.60%
- -35.15%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 3
- 5
- Recent ratings
- 19
- 8
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest CGC
- SEC Form SD filed by Canopy Growth Corporation
- Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
- Canopy Growth Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Canopy Growth Corporation filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits
- Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026
- Europe's Cannabis Boom Is Accelerating as Billions Flow into Licensed Markets
- Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options
- 'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign
- SEC Form 4 filed by Yanofsky Theresa
- SEC Form 4 filed by Atkins M Shan
Latest MDWD
- Director Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)
- Director Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)
- Director Rubinstein Samuel bought $2,150 worth of Ordinary Shares (150 units at $14.33), increasing direct ownership by 5% to 2,993 units (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by MediWound Ltd.
- MediWound to Report First Quarter 2026 Financial Results
- SEC Form 6-K filed by MediWound Ltd.
- Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
- MediWound to Present New EscharEx® Data at Leading Wound Care Conferences